The Canadian Nephrology Trials Network would like to acknowledge and congratulate their funding partner Can-SOLVE CKD Network on Phase 2 funding announcement. Can-SOLVE CKD will receive $3.75 million in new funding from CIHR matched by more than $8 million raised through the generous support of more than 60 partners.

 

The CNTN is thrilled about the investment being made by CIHR and Can-SOLVE CKD’s partner funders. Our organization is excited to continue our work towards improving the design, implementation and delivery of nephrology clinical trials in Canada.

CNTN Executive Co-Chairs Karthik Tennankore, François Madore, Hans Vorster, Dwight Sparkes

 

Can-SOLVE CKD Phase 2 is focused on mobilizing the findings of projects launched during the network’s first five years. Read the full network statement here:

https://cansolveckd.ca/news/11-8m-investment-to-support-can-solve-ckd-network-through-2027/